“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial comparing two combinations of chemotherapy for clear cell ovarian cancer (CCC1)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared paclitaxel and carboplatin with irinotecan and cisplatin for clear cell cancer, a rare form of ovarian cancer. Cancer Research UK supported this trial.
More about this trial
Doctors usually treat ovarian cancer with surgery and then chemotherapy. They often use the chemotherapy drugs paclitaxel (Taxol) and carboplatin. But these drugs don’t always work very well for clear cell ovarian cancer.
The aims of this trial were to find:
- how well irinotecan and cisplatin worked for clear cell ovarian cancer
- more about the side effects of this combination of treatment
Summary of results
The trial team found that irinotecan and cisplatin didn’t work any better than paclitaxel and carboplatin for clear cell ovarian cancer.
667 women took part. The team was able to look at the results for 619 women.
- 305 women had paclitaxel and carboplatin
- 314 women had irinotecan and cisplatin
After 2 years the team looked at the total number of women in each group who were still alive. They found this was:
- 247 women who had paclitaxel and carboplatin
- 248 women who had irinotecan and cisplatin
They also looked at how many women had no sign of cancer. They found this was:
- 226 women who had paclitaxel and carboplatin
- 222 women who had irinotecan and cisplatin
The most severe side effects of paclitaxel and carboplatin were:
- a drop in blood cells
- nerve damage (peripheral neuropathy)
- joint pain
The most severe side effects of irinotecan and cisplatin were:
- loss of appetite
- feeling or being sick
- high temperature and low white blood cells (febrile neutropenia)
The trial team concluded that irinotecan and cisplatin isn’t any better than paclitaxel and carboplatin as a treatment for clear cell ovarian cancer.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr John Green
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
NHS Greater Glasgow & Clyde
University of Glasgow
This is Cancer Research UK trial number CRUK/07/029.